#928 Subgroup analysis by chemotherapy regimen in the ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial evaluating atezolizumab combined with a platinum doublet and maintenance niraparib for late-relapsing ovarian cancer

Late Breaking Abstracts(2024)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要